Kartos Therapeutics
Kartos Therapeutics is a United States-based biotechnology company running 3 late-stage cancer trials of KRT-232 and Ruxolitinib in myeloproliferative neoplasms, endometrial cancer and diffuse large B-cell lymphoma.
Overview
Kartos Therapeutics, based in Redwood City, the United States, is a biotechnology company. Kartos Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapeutics for patients with cancer. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing KRT-232 and Ruxolitinib in myeloproliferative neoplasms, endometrial cancer, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia and hodgkin lymphoma. The largest, NCT05797831 (Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer), plans to enrol 268 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Scorecard
All companies- phase 1/2 +1
- targets +4
- modalities +2
Similar pages
not linked directly; found by shared links- CompanyRyvu Therapeutics
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Hodgkin lymphoma and the tag ctgov-sponsor.
- CompanyCuris
Shares Chronic lymphocytic leukaemia and the tag ctgov-sponsor.
- CompanyRanok Therapeutics (Hangzhou)
Shares Diffuse large B-cell lymphoma and the tag ctgov-sponsor.
- CompanyItalfarmaco
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag ctgov-sponsor.
- CompanyCellectis S.A.
Shares Hodgkin lymphoma and the tag ctgov-sponsor.
- CompanyHaihe Biopharma
Shares Hodgkin lymphoma and the tag ctgov-sponsor.
- CompanyShenzhen Ionova Life Sciences
Shares Endometrial cancer and the tag ctgov-sponsor.
- CompanyMiltenyi Biomedicine
Shares Diffuse large B-cell lymphoma and the tag ctgov-sponsor.